Skip to main content

Table 1 Baseline characteristics

From: Inverse association between central obesity and arterial stiffness in Korean subjects with metabolic syndrome: a cross-sectional cohort study

Characteristics

No MetS (NCEP-ATP III - / IDF -) (n = 1,608)

MetS (NCEP-ATP III +)

P

Total (n = 952)

With CeO (IDF +) (n = 804)

Without CeO (IDF -) (n = 148)

Age (years)

65 (60, 69)

64 (57, 69)

62 ± 8

61 ± 7

<0.001

Male gender (%)

31

36

32

62*

0.004

Smoking (%)

24

32

29

52*

<0.001

BMI (kg/m2)

24.0 ± 2.7

26.4 ± 2.9

26.8 ± 2.8

23.9 ± 1.9*

<0.001

Waist circumference (cm)

81 ± 8

89 ± 7

90 ± 7

81 ± 6*

<0.001

Heart rate (bpm)

66 ± 9

68 ± 10

68 ± 10

70 ± 11†

<0.001

SBP (mmHg)

120 ± 14

128 ± 15

128 ± 15

130 ± 15

<0.001

DBP (mmHg)

72 ± 9

77 ± 10

76 ± 10

79 ± 10†

<0.001

Antihypertensive medications (%)

29

66

67

66

<0.001

Total cholesterol (mg/dL)

201 ± 36

197 ± 37

197 ± 37

195 ± 36

0.006

Triglycerides (mg/dL)

94 (71, 118)

136 (103, 186)

164 ± 82

210 ± 80*

<0.001

HDL cholesterol (mg/dL)

57 (51, 63)

45 (37, 55)

47 ± 13

41 ± 11*

<0.001

LDL cholesterol (mg/dL)

110 (83, 127)

106 (83, 130)

121 ± 34

117 ± 33

0.096

Lipid lowering medications (%)

27

31

31

27

0.034

Creatinine (mg/dL)

0.78 (0.63, 0.95)

0.81 (0.68, 0.93)

0.79 ± 0.19

0.87 ± 0.19*

<0.001

Fasting glucose (mg/dL)

121 (105, 137)

125 (108, 143)

109 ± 24

114 ± 27‡

<0.001

Diabetes (%)

8

30

30

30

<0.001

Antidiabetic treatment (%)

7

25

82

84

<0.001

Duration of diabetes (months)

92 (44, 202)

92 (44, 152)

110 ± 85

107 ± 87

0.177

baPWV (cm/s)

1576 (1414, 1760)

1625 (1452, 1864)

1578 ± 270

1654 ± 315†

<0.001

  1. Continuous variables are expressed as mean ± SD or median [interquartile]. Categorical variables are presented as percentages. baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; CeO, central obesity; DBP, diastolic blood pressure; HDL, high-density lipoprotein; IDF, International Diabetes Federation; LDL, low-density lipoprotein; MetS, metabolic syndrome; NCEP-ATP III, National Cholesterol Education Program-Adult Treatment Panel III; SBP, systolic blood pressure. *p <0.001 vs. NCEP-ATP III + / IDF +, †p <0.01 vs. NCEP-ATP III + / IDF +, ‡p <0.05 vs. NCEP-ATP III + / IDF +.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us